Please assess the completion status of the following clinical trial:

Trial Title: Memantine - Communication Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatient at least 50 years of age and at least 8 years of education.~* The patient should have German as a mother-tongue or at least speak the language fluently in order to achieve similar scores in verbal tasks.~* Current diagnosis of probable Alzheimer's disease consistent with NINCDS- ADRDA criteria or with DSM IV TR criteria for Dementia of the Alzheimer's type.~* Mini Mental State Examination (MMSE) total score is less than 20~* Patients treated with any acetylcholinesterase inhibitor (AChEI) may be included, when treatment has started at least 6 months prior screening and was stable during the last 3 months.~Exclusion Criteria:~* Any type of evident aphasia, which may interfere with patient's communication difficulties caused by Alzheimer's disease~* History of severe drug allergy, or hypersensitivity, or patients with known hypersensitivity to amantadine, lactose.~* Evidence (including CT/MRI results) of any clinically significant central nervous system disease other than Alzheimer's disease.~* Modified Hachinski Ischemia score greater than 4 at screening.~* Current evidence of clinically significant systemic disease~* Known or suspected history of alcoholism or drug abuse within the past 10 years.~* Previous treatment with memantine or participation in an investigational study with memantine.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).